Naloxone precipitates nicotine abstinence syndrome in the rat - PubMed (original) (raw)

Naloxone precipitates nicotine abstinence syndrome in the rat

D H Malin et al. Psychopharmacology (Berl). 1993.

Abstract

Recently, a rodent model of nicotine abstinence syndrome has been developed based on continuous subcutaneous infusion of nicotine tartrate and observing the frequency of spontaneous behavioral signs following termination of infusion. The observed signs closely resemble those commonly seen in rat opiate abstinence syndrome, raising the possibility that there is an endogenous opioid component in nicotine dependence. The present study demonstrates that the opiate antagonist naloxone can precipitate an abstinence syndrome in nicotine-dependent rats. Fourteen rats were infused for 7 days with 9 mg/kg/day nicotine tartrate in saline via an Alzet osmotic minipump. Fourteen rats were sham-operated and remained nicotine-naive. Half of each group received 4.5 mg/kg naloxone SC immediately before a "blind" 15-min observation, while the other half received saline alone. ANOVA revealed significant nicotine infusion, naloxone injection and interaction effects. Post-hoc analysis showed that the nicotine-infused rats injected with naloxone had significantly more signs than all other groups (P < 0.01). In a second experiment, 2 mg/kg morphine sulfate SC produced a significant (P < 0.01) 91.2% reduction of spontaneous abstinence signs observed 21 h after termination of nicotine infusion. These results are consistent with the hypothesized endogenous opioid component in nicotine dependence and abstinence syndrome.

PubMed Disclaimer

Similar articles

• Nicotine alleviation of nicotine abstinence syndrome is naloxone-reversible.
  Malin DH, Lake JR, Payne MC, Short PE, Carter VA, Cunningham JS, Wilson OB. Malin DH, et al. Pharmacol Biochem Behav. 1996 Jan;53(1):81-5. doi: 10.1016/0091-3057(95)00202-2. Pharmacol Biochem Behav. 1996. PMID: 8848464
• The nicotinic antagonist mecamylamine precipitates nicotine abstinence syndrome in the rat.
  Malin DH, Lake JR, Carter VA, Cunningham JS, Hebert KM, Conrad DL, Wilson OB. Malin DH, et al. Psychopharmacology (Berl). 1994 Jun;115(1-2):180-4. doi: 10.1007/BF02244770. Psychopharmacology (Berl). 1994. PMID: 7862893
• Nicotine abstinence syndrome precipitated by an analog of neuropeptide FF.
  Malin DH, Lake JR, Short PE, Blossman JB, Lawless BA, Schopen CK, Sailer EE, Burgess K, Wilson OB. Malin DH, et al. Pharmacol Biochem Behav. 1996 Jul;54(3):581-5. doi: 10.1016/0091-3057(95)02279-1. Pharmacol Biochem Behav. 1996. PMID: 8743632
• The nitric oxide synthesis inhibitor nitro-L-arginine (L-NNA) attenuates nicotine abstinence syndrome in the rat.
  Malin DH, Lake JR, Shenoi M, Upchurch TP, Johnson SC, Schweinle WE, Cadle CD. Malin DH, et al. Psychopharmacology (Berl). 1998 Dec;140(3):371-7. doi: 10.1007/s002130050778. Psychopharmacology (Berl). 1998. PMID: 9877017
• [Involvement of the amygdala on place aversion induced by naloxone in single-dose morphine-treated rats].
  Ishida S, Shimosaka R, Kawasaki Y, Jin C, Kitamura Y, Araki H, Sendo T, Gomita Y. Ishida S, et al. Yakugaku Zasshi. 2008 Mar;128(3):395-403. doi: 10.1248/yakushi.128.395. Yakugaku Zasshi. 2008. PMID: 18311059 Review. Japanese.

Cited by

• Achieving Smoking Cessation Among Persons with Opioid Use Disorder.
  Vlad C, Arnsten JH, Nahvi S. Vlad C, et al. CNS Drugs. 2020 Apr;34(4):367-387. doi: 10.1007/s40263-020-00701-z. CNS Drugs. 2020. PMID: 32107731 Free PMC article. Review.
• Nicotine Gateway Effects on Adolescent Substance Use.
  Ren M, Lotfipour S. Ren M, et al. West J Emerg Med. 2019 Aug 20;20(5):696-709. doi: 10.5811/westjem.2019.7.41661. West J Emerg Med. 2019. PMID: 31539325 Free PMC article. Review.
• Exposure to passive nicotine vapor in male adolescent rats produces a withdrawal-like state and facilitates nicotine self-administration during adulthood.
  Kallupi M, de Guglielmo G, Larrosa E, George O. Kallupi M, et al. Eur Neuropsychopharmacol. 2019 Nov;29(11):1227-1234. doi: 10.1016/j.euroneuro.2019.08.299. Epub 2019 Aug 26. Eur Neuropsychopharmacol. 2019. PMID: 31462388 Free PMC article.
• Smokers with opioid use disorder may have worse drug use outcomes after varenicline than nicotine replacement.
  Martin RA, Rohsenow DJ, Tidey JW. Martin RA, et al. J Subst Abuse Treat. 2019 Sep;104:22-27. doi: 10.1016/j.jsat.2019.06.005. Epub 2019 Jun 10. J Subst Abuse Treat. 2019. PMID: 31370981 Free PMC article. Clinical Trial.
• Therapeutic challenges for concurrent ethanol and nicotine consumption: naltrexone and varenicline fail to alter simultaneous ethanol and nicotine intake by female alcohol-preferring (P) rats.
  Waeiss RA, Knight CP, Hauser SR, Pratt LA, McBride WJ, Rodd ZA. Waeiss RA, et al. Psychopharmacology (Berl). 2019 Jun;236(6):1887-1900. doi: 10.1007/s00213-019-5174-y. Epub 2019 Feb 13. Psychopharmacology (Berl). 2019. PMID: 30758525 Free PMC article.

References

1. 1. Peptides. 1987 Nov-Dec;8(6):1035-43 - PubMed
2. 1. Drug Alcohol Depend. 1990 Aug;26(1):85-7 - PubMed
3. 1. Psychopharmacology (Berl). 1983;81(1):61-7 - PubMed
4. 1. Neurosci Lett. 1990 May 18;113(1):40-6 - PubMed
5. 1. Psychopharmacology (Berl). 1988;96(1):29-35 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Springer

• Other Literature Sources

  • The Lens - Patent Citations Database